Effect of novel β2 receptor agonist trantinterol on cytochrome P450 mRNA expression in HepG2 cells

Yan-tong SUN,Ying-jie GUO,Meng-liang ZHANG,Xiang-yong CUI,Jing-kai GU
DOI: https://doi.org/10.13481/j.1671-587x.2010.05.074
2010-01-01
Abstract:Objective To study the effect of trantinterol, a potent and highly selective (32 receptor agonist, on the cytochrome P450 enzymes (CYP450) mRNA expression and provide a theoretical basis for clinical drug combination. Methods The cell proliferation of HepG2 cells treated with 2.4, 12, 60, 300, 1 200 and 4 800ng.L-1 trantinterol was analyzed by MTT. The mRNA expression levels of CYP1A1, CYP2E1 and CYP3A5 in HepG2 cells were examined using the real-time quantitative reverse-transcriptase polymerase chain reaction in human hepatoma HepG2 cells. Results Different concentrations of trantinterol didn' t inhibit the proliferation of HepG2 cells (P>0. 05). Compared with control group, the mRNA expressions of CYP2E1 and CYP3A5 in trantinterol groups had no change, while the mRNA expression of CYP1A1 was inhibited (P<0. 01). Conclusion Exposure of HepG2 cells to trantinterol has no effect on the mRNA expressions of CYP2E1 and CYP3A5 but inhibit the mRNA expression of CYP1A1.
What problem does this paper attempt to address?